Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Breast Cancer

  Free Subscription


Articles published in Histopathology

Retrieve available abstracts of 73 articles:
HTML format



Single Articles


    August 2026
  1. QUINN C, Tan PH, Allison KH, Brogi E, et al
    World Health Organization classification of tumours of the breast 6th edition 2026.
    Histopathology. 2026;89:199-218.
    PubMed     Abstract available


  2. LAOKULRATH N, Lau HY, Gudi M, Rakha E, et al
    Attenuated to absent myoepithelial cells in benign and non-invasive breast lesions-potential diagnostic pitfalls.
    Histopathology. 2026;89:219-239.
    PubMed     Abstract available


  3. KOONG JET, Shafique A, Md Nasir ND, Han A, et al
    Artificial intelligence modelling in grading breast phyllodes tumours.
    Histopathology. 2026;89:383-389.
    PubMed     Abstract available


    July 2026
  4. SHAABAN AM, Dodson A, Rakha E, Ellis I, et al
    UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer.
    Histopathology. 2026 Jul 18. doi: 10.1111/his.70235.
    PubMed     Abstract available


  5. MARABI M, Li Y, Aphivatanasiri C, Tsang JY, et al
    Calcification and tumour-infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)-negative ductal carcinoma in situ diagnosed on core needle biopsy.
    Histopathology. 2026;89:122-135.
    PubMed     Abstract available


  6. KOSHY R, Jain PV, Jorns JM
    Characterizing pseudoangiomatous stromal hyperplasia (PASH) of the breast.
    Histopathology. 2026;89:174-180.
    PubMed     Abstract available


    June 2026
  7. GROSSE C, Grosse A, Noack P, Preuss CI, et al
    Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer.
    Histopathology. 2026 Jun 18. doi: 10.1111/his.70203.
    PubMed     Abstract available


  8. LIU L, Graff SL, Hacking S, Cheng L, et al
    Genomic and clinicopathological characteristics of low oncotype recurrent score breast cancers with subsequent metastasis.
    Histopathology. 2026;88:1451-1458.
    PubMed     Abstract available


    May 2026
  9. PANG JB, Gorringe KL, Tan PH, Fox SB, et al
    Molecular pathology of phyllodes tumours of the breast-much more than MED12.
    Histopathology. 2026;88:1115-1125.
    PubMed     Abstract available


  10. INGYIN H, Solomon JP, Li Y, Xu D, et al
    Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.
    Histopathology. 2026;88:1229-1235.
    PubMed     Abstract available


  11. KRINGS G, Hashem S, Apushkin MA, Ang-Rabanes TL, et al
    Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.
    Histopathology. 2026;88:1212-1220.
    PubMed     Abstract available


    April 2026
  12. SHEPHERD DJ, Craig C, Valencia-Guerrero AL, Chattu S, et al
    Prostein (p501s) is expressed in primary extramammary Paget disease.
    Histopathology. 2026;88:1094-1098.
    PubMed     Abstract available


  13. MISRA S, Gudi M, Allison KH, Brogi E, et al
    Mucin-producing breast lesions: a practical approach to diagnosis.
    Histopathology. 2026;88:939-957.
    PubMed     Abstract available


  14. ZUO K, Shui R, Xu X, Yu B, et al
    Apocrine encapsulated papillary carcinoma: a comprehensive clinicopathological analysis of 28 cases.
    Histopathology. 2026;88:1075-1083.
    PubMed     Abstract available


    March 2026

  15. Correction to 'A simple digital image analysis system for automated Ki67 assessment in primary breast cancer'.
    Histopathology. 2026 Mar 11. doi: 10.1111/his.70123.
    PubMed    


  16. RAKHA EA, Tan PH, Raymond WA
    The spectrum of breast in situ papillary carcinomas with invasion and invasive breast carcinomas with papillary features: an overview of histological subtypes and diagnostic challenges.
    Histopathology. 2026;88:747-768.
    PubMed     Abstract available


  17. NAKAMURA H, Kukita Y, Kittaka N, Kusama H, et al
    Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis.
    Histopathology. 2026;88:790-809.
    PubMed     Abstract available


    February 2026
  18. D'ARRIGO C, Tuzlali S, Barroso-Sousa R, El Saghir NS, et al
    Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study.
    Histopathology. 2026 Feb 22. doi: 10.1111/his.70091.
    PubMed     Abstract available


  19. LLEWELLYN A, Brown A, Morel J, Naidoo K, et al
    To VAE or not to VAE: outcomes of radial scars/complex sclerosing lesions and papillary lesions without atypia in the King's College Hospital breast service (2017-2023).
    Histopathology. 2026;88:583-590.
    PubMed     Abstract available


    January 2026
  20. HUANG CY, Wang YJ, Hsieh MS, Lin PY, et al
    Tumour-infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies.
    Histopathology. 2026;88:471-487.
    PubMed     Abstract available


  21. YE Q, Estrella J, Kalhor N, Liu A, et al
    TRPS1 expression in neuroendocrine neoplasms of breast and other organs.
    Histopathology. 2026;88:524-532.
    PubMed     Abstract available


    December 2025
  22. KAIN ZE, Baez-Navarro X, Linn SC, van Deurzen CHM, et al
    Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.
    Histopathology. 2025;87:951-955.
    PubMed     Abstract available


  23. SUN M, Fu L, Ren H, Wang J, et al
    Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features.
    Histopathology. 2025;87:904-914.
    PubMed     Abstract available


  24. STA INES FM, Eadara A, Quddus MR, Sung CJ, et al
    Re-appraisal of mucocele-like lesion of the breast with atypia: study of 34 cases with focus on impact of type and extent of atypia on upgrade.
    Histopathology. 2025;87:943-950.
    PubMed     Abstract available


    September 2025
  25. MAKHLOUF S, Almalki N, Sheha A, Atallah NM, et al
    Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
    Histopathology. 2025 Sep 12. doi: 10.1111/his.15557.
    PubMed     Abstract available


    August 2025
  26. SALISBURY T, Rendi M, Bhalli R, Bean GR, et al
    DCIS-like invasive carcinoma of the breast with tumour-associated microvasculature mimicking myoepithelium: a diagnostic pitfall.
    Histopathology. 2025;87:246-257.
    PubMed     Abstract available


  27. HAN R, Hashmi AA, Wen HY, Murray M, et al
    Clinicopathological features of microinvasive lobular carcinoma.
    Histopathology. 2025;87:235-245.
    PubMed     Abstract available


  28. TAN PH, Ellis IO, Allison KH, Badve SS, et al
    Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
    Histopathology. 2025;87:169-182.
    PubMed     Abstract available


    July 2025
  29. LEE AHS, Rakha EA, Hodi Z, Abbas A, et al
    Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy.
    Histopathology. 2025;87:58-67.
    PubMed     Abstract available


    June 2025
  30. LAOKULRATH N, Nasir NDM, Gudi M, Tan PH, et al
    Diagnostic accuracy and challenges of intraoperative frozen section evaluation for axillary sentinel lymph node biopsy and breast margins.
    Histopathology. 2025;86:1121-1136.
    PubMed     Abstract available


  31. AL-REFAI R, Ali A, Roychoudhury S, Bendari A, et al
    Male breast atypical ductal hyperplasia (ADH): clinicopathological insights from a rare cohort.
    Histopathology. 2025;86:1137-1146.
    PubMed     Abstract available


    May 2025
  32. SOKOLOVA A, Joshi V, Chittoory H, Walsh M, et al
    ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.
    Histopathology. 2025 May 13. doi: 10.1111/his.15465.
    PubMed     Abstract available


  33. EL SHEIKH S, Mansour MA, Provenzano E, Shaaban A, et al
    Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology.
    Histopathology. 2025;86:953-966.
    PubMed     Abstract available


  34. HONG R, Wang H, Lin Y, Yin X, et al
    The clinicopathological and molecular features of primary high-grade neuroendocrine tumour in the breast.
    Histopathology. 2025;86:900-915.
    PubMed     Abstract available


    April 2025
  35. BOYRAZ B, Robinson B, Lindeman N, Hoda SA, et al
    Subareolar sclerosing ductal hyperplasia shows PI3K pathway alterations.
    Histopathology. 2025;86:824-827.
    PubMed     Abstract available


  36. KHEDR M, Gandhi S, Roy AM, Alharbi M, et al
    Breast biomarkers evolution between primary and distant metastasis: incidence and significance.
    Histopathology. 2025;86:793-804.
    PubMed     Abstract available


  37. KATAYAMA A, Makhlouf S, Toss MS, Oyama T, et al
    Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.
    Histopathology. 2025;86:813-823.
    PubMed     Abstract available


  38. KRINGS G, Shamir ER, Lae M, Bean GR, et al
    Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.
    Histopathology. 2025;86:779-792.
    PubMed     Abstract available


  39. YANG E, Fineberg S, Mohamed A, Brogi E, et al
    Variability in the diagnosis and reporting of metaplastic breast carcinoma: results of an international survey.
    Histopathology. 2025;86:742-749.
    PubMed     Abstract available


    March 2025
  40. KIM M, Lee M, Lee A, Choi BO, et al
    Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer.
    Histopathology. 2025 Mar 31. doi: 10.1111/his.15453.
    PubMed     Abstract available


  41. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    PubMed     Abstract available


  42. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    PubMed     Abstract available


    February 2025
  43. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    PubMed     Abstract available


  44. YANG E, D'Alfonso TM, Morrow M, Brogi E, et al
    Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation.
    Histopathology. 2025;86:441-449.
    PubMed     Abstract available


  45. TAHA SR, Boulos F
    E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.
    Histopathology. 2025;86:327-340.
    PubMed     Abstract available


    January 2025
  46. ASHI A, Awaji AA, Bond J, Johnson CA, et al
    Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.
    Histopathology. 2025 Jan 7. doi: 10.1111/his.15399.
    PubMed     Abstract available


  47. LEE AHS, Hodi Z, Abbas A, Ellis IO, et al
    HER2-positive grade 1 invasive carcinomas of the breast.
    Histopathology. 2025;86:278-284.
    PubMed     Abstract available


    December 2024
  48. WANG Y, Liu L, Graff SL, Cheng L, et al
    Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer.
    Histopathology. 2024 Dec 17. doi: 10.1111/his.15395.
    PubMed     Abstract available


  49. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    PubMed     Abstract available


  50. HEMPENIUS MA, Eenkhoorn MA, Hoeg H, Dabbs DJ, et al
    Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.
    Histopathology. 2024;85:920-928.
    PubMed     Abstract available


    October 2024
  51. MATSUMOTO H, Miyata R, Tsuruta Y, Nakada N, et al
    Ki-67 evaluation using deep-learning model-assisted digital image analysis in breast cancer.
    Histopathology. 2024 Oct 31. doi: 10.1111/his.15356.
    PubMed     Abstract available


  52. WANG Y, Liu L, Graff SL, Cheng L, et al
    Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients.
    Histopathology. 2024 Oct 22. doi: 10.1111/his.15345.
    PubMed     Abstract available


    September 2024
  53. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
    Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
    Histopathology. 2024;85:510-520.
    PubMed     Abstract available


  54. BATRA H, Bose PSC, Ding Y, Dai A, et al
    MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
    Histopathology. 2024;85:503-509.
    PubMed     Abstract available


  55. TURASHVILI G
    Nonneoplastic and neoplastic sclerosing lesions of the breast.
    Histopathology. 2024;85:383-396.
    PubMed     Abstract available


  56. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
    Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
    Histopathology. 2024;85:397-404.
    PubMed     Abstract available


  57. ELLIS I, Webster F, Allison KH, Dang C, et al
    Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;85:418-436.
    PubMed     Abstract available


    August 2024
  58. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
    Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
    Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
    PubMed     Abstract available


    July 2024
  59. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    PubMed     Abstract available


  60. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    PubMed     Abstract available


  61. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    PubMed     Abstract available


    June 2024
  62. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    PubMed     Abstract available


  63. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    PubMed     Abstract available


  64. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    PubMed     Abstract available


  65. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    PubMed     Abstract available


    May 2024
  66. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    PubMed     Abstract available


  67. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    PubMed     Abstract available


    April 2024
  68. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    PubMed     Abstract available


  69. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    PubMed     Abstract available


  70. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    PubMed     Abstract available


  71. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    PubMed     Abstract available


    March 2024
  72. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    PubMed     Abstract available


    November 2023
  73. CSERNI G, Kalman E, Udvarhelyi N, Papp E, et al
    Evaluation of the routine use of E-cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study.
    Histopathology. 2023;83:810-821.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum